143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab

✍ Scribed by William J. Sandborn; Severine Vermeire; Geert R. D'Haens; Jean-Frederic Colombel; Richard N. Fedorak; Martina E. Spehlmann; Douglas C. Wolf; Maria T. Abreu; Krassimir Mitchev; Corinne Jamoul; Paul J. Rutgeerts

• Book ID: 119429983
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 102 KB
• Volume: 136
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/s0016-5085(09)60126-8